FELIQS, a Japanese startup company funded with a seed round of $2.5 million, develops a portfolio of two patent-protected drug product candidates targeting two attractive multi-billion-dollar markets in ophthalmology:
- dry Age-related macular degeneration (AMD) – FLQ-104, a proprietary anti-ferroptosis inhibitor for earlier intervention to treat AMD. FLQ-104 will be in Phase I dosing planned for 2024.
- Retinopathy of prematurity (ROP) – FLQ-101, a lipid modulator repurposed to prevent ROP. FLQ-101 will be in Phase I/II dosing planned in the US for 2024.
Each developmental candidate is identified through FELIQS’s proprietary screening platform targeting lipid peroxidation/ ferroptosis with proven efficacy from past prospective human clinical trials.
Each developmental candidate offers an attractive value proposition in terms of safety and convenient route of administration (oral for AMD, i.v. for ROP).
FELIQS technology is also expandable to other indications like dermatology.
- dry Age-related macular degeneration (AMD) – FLQ-104, a proprietary anti-ferroptosis inhibitor for earlier intervention to treat AMD. FLQ-104 will be in Phase I dosing planned for 2024.
- Retinopathy of prematurity (ROP) – FLQ-101, a lipid modulator repurposed to prevent ROP. FLQ-101 will be in Phase I/II dosing planned in the US for 2024.
Each developmental candidate is identified through FELIQS’s proprietary screening platform targeting lipid peroxidation/ ferroptosis with proven efficacy from past prospective human clinical trials.
Each developmental candidate offers an attractive value proposition in terms of safety and convenient route of administration (oral for AMD, i.v. for ROP).
FELIQS technology is also expandable to other indications like dermatology.
Speaker
